Serious Illness Communication Project
18 Years
N/A
Both
End of Life Care
Trial Information
Serious Illness Communication Project
The subjects of this study will be the clinicians (physicians and nurse practitioners)
conducting the SICC conversations, their patient with high-risk cancers, and a friend or
family member of the patient.
Clinician
Inclusion Criteria:
1. Dana-Farber Cancer Center clinician
2. Care for patients with selected high-risk cancers (breast oncology, gastrointestinal
oncology, head and neck oncology, genitourinary oncology, hematologic malignancies,
melanoma, neuro-oncology, sarcoma, and thoracic oncology) or patients in Phase I
Clinical Trials
Clinician Exclusion Criteria:
1. DFCI Gynecology-Oncology specialist
Patient Inclusion Criteria
1. Over 18 years of age
2. English speaker
3. Patient at Dana-Farber Cancer Institute
4. Diagnosis of one of the following high mortality or advanced cancers: breast,
gastric, intestinal, esophageal, pancreatic, biliary, colorectal, hepatocellular,
head and neck, renal, bladder, prostate, acute myeloid lymphoma (AML), acute
lymphoblastic lymphoma (ALL), melanoma, glioblastoma multiforme (GBM), sarcoma, and
lung; or enrollment in a Phase I clinical trial.
5. Ability to provide consent
Patient Exclusion Criteria
1. Diagnosis of advanced obstetric-gynecological cancer
Family Member Inclusion Criteria
1. Over 18 years of age
2. English speaker
3. Friend or family member of study patient (Health care proxy, or close friend or
family member who is involved in helping the patient think about decisions related to
their health care)
4. Ability to provide consent
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Outcome Measure:
Enhanced goal-consistent care
Outcome Description:
Patients whose physician is trained to use and adheres to the SICC will receive care that is more consistent with their key life priorities during the last week and the last 3 months of life than patients whose physician is not trained to use the SICC. Goal consistent care will be measured by comparing patient identified goals to chart review and family report.
Outcome Time Frame:
up to 2 years
Safety Issue:
No
Principal Investigator
Rachelle Bernacki, MD, MS
Investigator Role:
Principal Investigator
Investigator Affiliation:
Dana-Farber Cancer Institute
Authority:
United States: Institutional Review Board
Study ID:
12-027
NCT ID:
NCT01786811
Start Date:
June 2012
Completion Date:
June 2015
Related Keywords:
- End of Life Care
Name | Location |
|---|---|
| Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
